electroCore, Inc.

NasdaqCM ECOR

electroCore, Inc. Current Liabilities for the quarter ending September 30, 2024: USD 7.91 M

electroCore, Inc. Current Liabilities is USD 7.91 M for the quarter ending September 30, 2024, a -7.01% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

electroCore, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 8.51 M, a 28.09% change year over year.
electroCore, Inc. Current Liabilities for the quarter ending September 30, 2022 was USD 6.64 M, a 15.74% change year over year.
electroCore, Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 5.74 M, a -1.25% change year over year.
electroCore, Inc. Current Liabilities for the quarter ending September 30, 2020 was USD 5.81 M, a -43.28% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqCM: ECOR

electroCore, Inc.

CEO	Mr. Daniel S. Goldberger
IPO Date	June 22, 2018
Location	United States
Headquarters	200 Forge Way
Employees	68
Sector	Technology
Industries 3D Printing Biotechnology Clinical Trials Computers Drugstores & Retail Pharmacies Hardware & Electronics Medical Instruments Pharmaceuticals

Description

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Key trends

Past 5 years